Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-12-19
2009-12-22
Arnold, Ernst V (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S649000, C514S079000, C514S089000, C514S090000, C514S360000, C514S365000, C514S492000, C514S908000
Reexamination Certificate
active
07635708
ABSTRACT:
The present invention is based on the finding that activation of PPARγ plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPARγ agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proliferation of such cells.
REFERENCES:
patent: 5071773 (1991-12-01), Evans et al.
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5514821 (1996-05-01), Bennani et al.
patent: 5521202 (1996-05-01), Yano et al.
patent: 5552271 (1996-09-01), Pfahl et al.
patent: 5798375 (1998-08-01), Tsujita et al.
patent: 5814647 (1998-09-01), Urban et al.
patent: 6207690 (2001-03-01), Urban et al.
patent: WO 93/21146 (1993-10-01), None
patent: WO 95/10271 (1995-04-01), None
patent: WO 95/10271 (1995-04-01), None
patent: WO 95/11974 (1995-05-01), None
patent: WO 95/11974 (1995-05-01), None
patent: WO 95/18533 (1995-07-01), None
patent: WO 95/35108 (1995-12-01), None
patent: WO 96/01317 (1996-01-01), None
patent: WO 96/01317 (1996-01-01), None
patent: WO 96/01430 (1996-01-01), None
patent: WO 96/01430 (1996-01-01), None
patent: WO 96/05165 (1996-02-01), None
patent: WO 96/33724 (1996-10-01), None
patent: WO 96/33724 (1996-10-01), None
patent: WO 96/34943 (1996-11-01), None
patent: WO 96/40128 (1996-12-01), None
patent: WO 96/40128 (1996-12-01), None
patent: WO 97/10819 (1997-03-01), None
patent: WO 97/17091 (1997-05-01), None
Hasida, T., Todo, S., and Imashuku, S. Role of Adenosine 3′5′-Cyclic Monophosphate in Antineoplastic Effect of Prostaglandins (PGE1, PGE2, PGD2 and PGA1) on Humna Neuroblastoma Cells. Prostaglandins Leukotrienes and Essential Fattly Acids 1988, 33, 61.
Sohlenius, A-K., et al. Synergistic induction of acyl-CoA oxidase activity , an indicator of peroxisome proliferation, by arachidonic acid and retinoic acid in Morris hepatoma 7800C1 cells. Biochim. Biophys. Acta. 1995, 1258, 257.
Ip, M. M., Sylvester, P. W., and Schenkel, L. Antitumor Efficacy in Rats of CGP 19984, a Thiazolidinedione Derivative That Inhibits Luteinizing Hormone Secretion. Cancer Research 1986, 46, 1735.
Chawla, et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation Endocrinology 1994, 135(2), 798-800.
Nikitakis et al. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells British Journal of Cancer 2002, 87, 1396-1403.
Satoh et al. (Life Sciences 1996, 59(14), 1103-1108).
MedlinePlus medical encyclopedia: prostate cancer Sep. 11, 2006. [online] retrieved from http://www.nlm.nih.gov/medlineplus/ency/article/000380.htm; retrieved on Sep. 27, 2007. 5 pages.
Zips et al. In vivo 2005, 19, 1-8.
Sikora Current Science 2001, 81(5), 549-554.
Adachi, H. et al., “Suppression by Retinoids of the Induction of the CCAAT/Enhancer-Binding Protein α and the Nuclear Receptors PPPARγ and RORγ During Adipocyte differentiation of 3T3-L1 Cells,” (1996)Molecular and Cellular Differentiation4:365-381.
Allen, P.W. “Recent Advances in Tumors of Adipose Tissue,” (1995)Current Topics in Pathology89:215-239.
Amri, E-Z. et al., “Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes,” (1995)The Journal of Biological Chemistry270:2367-2371.
Asou, H. et al., “Growth Inhibition of Myeloid Leukemia Cells by Troglitazone, a Ligand for Peroxisome Proliferator Activated Receptor γ (PPAR γ) and Retinoids,”(1997)Blood90:284B.
Bocos, C. et al., “Fatty Acid Activation of Peroxisome Proliferator-activated Receptor (PPAR),” (1995)J. Steroid Biochem. Molec. Biol.53:467-473.
Braissant, O. et al., “Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution of PPAR-α, -β, and -γ in the Adult Rat,” (1996)Endocrinology137:354-366.
Espandiari, P. et al., “The Herbicide Dicamba (2-Methoxy-3,6-dichlorobenzoic Acid) Is a Peroxisome Proliferator in Rats,” (1995)Fundamental and Applied Toxicology26:85-90.
Fleisch, J. et al., “A Brief Review of Preclinical and Clinical Studies with LY171883 and Some Comments on Newer Cysteinyl Leukotriene Receptor Antagonists,” (1988)Annals New York Academy of Sciences524:356-368.
Forman, B. et al., “15-Deoxy-Δ12,14-Prostaglandin J2Is a Ligand for the Adipocyte Determination Factor PPARγ,” (1995)Cell83:803-812.
Green, S. “PPAR: a mediator of peroxisome proliferator action,” (1995)Mutation Research333:101-109.
Green, S. et al. “Peroxisome proliferator-activated receptors: finding the orphan a home,” (1994)Molecular and Cellular Endocrinology100:149-153.
Green, S. et al., “The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment,” (1992)Toxicology Letters64/65:131-139.
Hertz, R. et al., “Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs,” (1995)The Journal of Biological Chemistry270:13470-13475.
Juge-Aubry, C. et al., “Peroxisome Proliferator-activated Receptor Mediates Cross-talk with Thyroid Hormone Receptor by Competition for Retinoid X Receptor,” (1995)The Journal of Biological Chemistry270:18117-18122.
Kliewer, S. et al., “A Prostaglandin J2Metabolite Binds Peroxisome Proliferator-Activated Receptor γ and Promotes Adipocyte Differentiation,” (1995)Cell83:813-819.
Lambe, K. et al., “A Human Peroxysome-Proliferator-Activated Receptor γ is Activated by Inducers of Adipogenesis, Including thiazolidinedione Drugs,” (1996)Eur. J. Biochem.239:1-7.
Lefèbvre, P. et al., “Improving the action of insulin,” (1995)Clin. Invest. Med.18:340-347.
Lehmann, J. et al., “Retinoids Selective for Retinoid X Receptor Response Pathways,” (1992)Science,258:1944-1946.
Lehmann, J. et al., “An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ),” (1995)The Journal of Biological Chemistry270:12953-12956.
Motojima, K., “Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions,” (1993)Cell Structure and Function18:267-277.
Niemiec, S. et al., “Influence of Nonionic Liposomal Composition on Topical Delivery of Peptide Drugs into Pilosebaceous Units: An in Vivo Study Using the Hamster Ear Model,” (1995)Pharmaceutical Research12:1184-1188.
Nilsson, A. et al., “Potentiating effects of clofibric acid on the differentiation of HL-60 human promyelocytic leukemia cells induced by retinoids,” (1995)European Journal of Cell Biology67:379-385.
Palmer, C. et al., “Novel Sequence Determinants in Peroxisome Proliferator Signaling,” (1995)The Journal of Biological Chemistry270:16114-16121.
Schoonjans, K. et al., “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation,” (1996)Biochimica et Biophysica Acta1302:93-109.
Shao, D. et al.: “Peroxisome Proliferator Activated Receptor γ, CCAAT/Enhancer-Binding Protein α, and Cell Cycle Status Regulate the Commiment to Adipocyte Differentiation,” (1997)J. Biol. Chem.272:21473-21478.
Smith, W., “Prostanoid biosynthesis and mechanisms of action,” (1992)Am. J. Physiol.263:F181-F191.
Smith, W., “The eicosanoids and their biochemical mechanisms of action,” (1989)Biochem. J.259:315-324.
Spiegelman, B. et al., “PPAR-gamma and the Transcriptional Basis of Adipogenesis,” (1997)FASEB Journal11:A880 (abstract 130).
Sreekantaiah, C. et al., “Chromosomal Aberrations in Soft Tissue Tumors: Relevance to Diagnosis, Classification, and Molecular Mechanisms,” (1994)American Journal of Pathology144:1121
Altiok Soner
Mueller Elisabetta
Sarraf Pasha
Singer Samuel
Spiegelman Bruce M.
Arnold Ernst V
Dana-Farber Cancer Institute
Foley & Hoag LLP
LandOfFree
Methods and pharmaceutical compositions for inhibiting tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceutical compositions for inhibiting tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceutical compositions for inhibiting tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4083693